STOK
Price
$19.79
Change
+$0.49 (+2.54%)
Updated
Aug 28, 04:59 PM (EDT)
Capitalization
1.08B
74 days until earnings call
SYRE
Price
$16.72
Change
-$0.42 (-2.45%)
Updated
Aug 28, 04:59 PM (EDT)
Capitalization
1.01B
70 days until earnings call
Interact to see
Advertisement

STOK vs SYRE

Header iconSTOK vs SYRE Comparison
Open Charts STOK vs SYREBanner chart's image
Stoke Therapeutics
Price$19.79
Change+$0.49 (+2.54%)
Volume$27.54K
Capitalization1.08B
Spyre Therapeutics
Price$16.72
Change-$0.42 (-2.45%)
Volume$9.26K
Capitalization1.01B
STOK vs SYRE Comparison Chart in %
Loading...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
STOK vs. SYRE commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is STOK is a StrongBuy and SYRE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (STOK: $19.77 vs. SYRE: $16.72)
Brand notoriety: STOK and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: STOK: 83% vs. SYRE: 54%
Market capitalization -- STOK: $1.08B vs. SYRE: $1.01B
STOK [@Biotechnology] is valued at $1.08B. SYRE’s [@Biotechnology] market capitalization is $1.01B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

STOK’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • STOK’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, STOK is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

STOK’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 6 bullish TA indicator(s).

  • STOK’s TA Score: 4 bullish, 4 bearish.
  • SYRE’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than STOK.

Price Growth

STOK (@Biotechnology) experienced а +0.46% price change this week, while SYRE (@Biotechnology) price change was -0.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.11%. For the same industry, the average monthly price growth was +20.33%, and the average quarterly price growth was +29.99%.

Reported Earning Dates

STOK is expected to report earnings on Nov 11, 2025.

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+2.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
STOK($1.08B) has a higher market cap than SYRE($1.01B). STOK has higher P/E ratio than SYRE: STOK (22.18) vs SYRE (1.72). STOK YTD gains are higher at: 79.238 vs. SYRE (-26.375). STOK has higher annual earnings (EBITDA): 42.3M vs. SYRE (-222.15M). SYRE has more cash in the bank: 527M vs. STOK (248M). SYRE has less debt than STOK: SYRE (0) vs STOK (2.3M). STOK has higher revenues than SYRE: STOK (200M) vs SYRE (0).
STOKSYRESTOK / SYRE
Capitalization1.08B1.01B107%
EBITDA42.3M-222.15M-19%
Gain YTD79.238-26.375-300%
P/E Ratio22.181.721,293%
Revenue200M0-
Total Cash248M527M47%
Total Debt2.3M0-
FUNDAMENTALS RATINGS
STOK vs SYRE: Fundamental Ratings
STOK
SYRE
OUTLOOK RATING
1..100
2510
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
72
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
4697
PRICE GROWTH RATING
1..100
3561
P/E GROWTH RATING
1..100
1082
SEASONALITY SCORE
1..100
39n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

STOK's Valuation (58) in the null industry is in the same range as SYRE (72) in the Pharmaceuticals Major industry. This means that STOK’s stock grew similarly to SYRE’s over the last 12 months.

STOK's Profit vs Risk Rating (100) in the null industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that STOK’s stock grew similarly to SYRE’s over the last 12 months.

STOK's SMR Rating (46) in the null industry is somewhat better than the same rating for SYRE (97) in the Pharmaceuticals Major industry. This means that STOK’s stock grew somewhat faster than SYRE’s over the last 12 months.

STOK's Price Growth Rating (35) in the null industry is in the same range as SYRE (61) in the Pharmaceuticals Major industry. This means that STOK’s stock grew similarly to SYRE’s over the last 12 months.

STOK's P/E Growth Rating (10) in the null industry is significantly better than the same rating for SYRE (82) in the Pharmaceuticals Major industry. This means that STOK’s stock grew significantly faster than SYRE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
STOKSYRE
RSI
ODDS (%)
Bearish Trend 2 days ago
85%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 8 days ago
86%
Bullish Trend 2 days ago
85%
Declines
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RGECX10.960.05
+0.46%
Russell Inv Global Equity C
LMGAX29.26N/A
N/A
Lord Abbett Growth Opportunities A
LGLFX56.51N/A
N/A
Lord Abbett Growth Leaders F
PJEZX15.67N/A
N/A
PGIM US Real Estate Z
RIEAX13.15N/A
N/A
RBC International Equity A

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with IDYA. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+0.47%
IDYA - SYRE
61%
Loosely correlated
+0.56%
CGON - SYRE
61%
Loosely correlated
-2.03%
BEAM - SYRE
58%
Loosely correlated
+1.32%
XNCR - SYRE
57%
Loosely correlated
+1.52%
CRNX - SYRE
56%
Loosely correlated
-1.71%
More